Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-06-30 M&A Activity
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
M&A Activity Classification · 99% confidence The document explicitly announces a "proposed merger" between BerGenBio ASA and Oncoinvent ASA, detailing the terms, the resulting capital structure (including a planned rights issue), management changes, and conditions for completion. This content directly relates to a significant corporate transaction involving the combination of two entities, which falls under the category of M&A Activity (Takeover/Merger). The document is a detailed announcement, not a short notice, so it is not an RPA or RNS fallback. The most specific code is TAR (M&A Activity / Takeover/Merger Proposal).
2025-06-30 English
Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases - Attachment: 2025-06-18 Presentation of Ph
Regulatory Filings Classification · 95% confidence The document is a press release dated June 18, 2025, announcing an invitation to a presentation of final data from a clinical trial for the product Radspherin®. It explicitly states that a webcast will be held on that date to present the top-line results. This structure—announcing an upcoming event to discuss results or provide updates—is characteristic of an Earnings Release (ER) if it were about financial performance, or more generally, a Regulatory Filing (RNS) or a Report Publication Announcement (RPA) if it's announcing the release of specific data/results. Since the core purpose is to announce the presentation of clinical trial data (not the full financial report itself, nor a management change, nor a dividend), and it provides details for accessing the presentation (webcast link), it fits best as an announcement related to company information dissemination. Given the options, it is an announcement about the release of specific data/results, which often falls under RNS if it's not a standard ER or IR. However, since it is an announcement about the *release* of results via a presentation/webcast, and the document itself is short and serves as a notification, RPA (Report Publication Announcement) is a strong candidate if the presentation itself is considered the 'report'. If we consider this a general corporate update about data disclosure, RNS is the fallback. Since it is specifically announcing the presentation of data, and not the full financial report (10-K/IR) or a management discussion (MDA), and it's not a proxy/voting document, RNS is the most appropriate general regulatory announcement category for this type of corporate disclosure that doesn't fit the other specific categories like ER or DIV.
2025-06-18 English
Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases
Regulatory Filings Classification · 92% confidence The document is an invitation to a presentation regarding the final data from a clinical trial (Phase 1/2a for Radspherin®). It announces a specific event (webcast on June 18th, 2025) where results will be presented. It is not the full financial report (10-K, IR), nor is it the initial earnings release (ER). Since it is an announcement inviting stakeholders to view upcoming data/results presentation, it fits best as a general Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the context of inviting people to a presentation of clinical data, 'Investor Presentation' (IP) is the most fitting category, as these invitations often precede or accompany investor-focused materials. However, the document itself is purely an invitation to a webcast to discuss results, which is a common precursor to an Investor Presentation or a Call Transcript (if the call itself was transcribed). Since the core action is announcing the presentation of data, and it is not the full presentation document itself, it leans towards an announcement. If we consider the content is about presenting data, IP is plausible. If we consider it's just an announcement of an event, RPA or RNS applies. Given the focus on clinical data presentation, which is highly relevant to investors, I will classify it as an Investor Presentation (IP), assuming the invitation implies the presentation material itself is the focus, even if this specific text is just the invite. Alternatively, since it's an invitation to a presentation, it could be seen as a precursor to a Call Transcript (CT) if the presentation is structured like an earnings call Q&A, or an Investor Presentation (IP). Given the specific nature of presenting clinical trial data, IP is the strongest fit among the specific categories.
2025-06-18 English
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases - Attachment: 2506 Oncoinvent PM CRC Ph1-2a.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing positive topline data from a Phase 1/2a clinical trial (RAD-18-002) for a drug called Radspherin®. It details efficacy results (peritoneal recurrence-free survival), quotes investigators, and provides background on the drug and the company (Oncoinvent ASA). This type of announcement, which releases key financial/clinical results for a period or trial without being the full statutory report (like a 10-K or IR), aligns best with an Earnings Release (ER) or a general announcement. Since it is specifically announcing the results of a clinical trial, which is a key operational/financial milestone, 'ER' (Earnings Release) is the closest fit among the options for a major, periodic operational update, even though it's clinical data rather than quarterly revenue. Given the context of financial reporting databases, major clinical trial result announcements often fall under the 'ER' umbrella if a more specific clinical trial result code is unavailable, or sometimes under 'RNS' if it's purely regulatory news. However, the structure (headline results, quotes, forward-looking statements) strongly mimics an Earnings Release format used to communicate performance highlights. Since it is a major announcement of performance data, ER is chosen over the generic RNS, and it is clearly not a full report (10-K, IR) or a presentation (IP). Q2 2025
2025-06-18 English
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases
Earnings Release Classification · 95% confidence The document is a press release announcing positive topline data from a Phase 1/2a clinical trial (RAD-18-002) for a drug called Radspherin®. It details efficacy endpoints (peritoneal recurrence-free survival) and safety profiles, includes quotes from investigators and the CEO, and provides background on the company and the drug. This format—announcing key results from a study—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it is focused purely on announcing clinical trial results and not comprehensive financial performance for a fiscal period (which would be 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category for a major clinical data announcement that serves as an initial results highlight is 'Earnings Release' (ER), as these announcements often precede or substitute for a formal earnings report when clinical milestones are the primary focus. It is not a formal regulatory filing like a 10-K or AR, nor is it a simple announcement of a report publication (RPA). Q1 2025
2025-06-18 English
Minutes from the annual general meeting 2025
AGM Information Classification · 100% confidence The document is explicitly titled "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING" (MINUTES OF ANNUAL GENERAL MEETING) in both Norwegian and English. It details the proceedings, resolutions passed (including election of chairperson, approval of accounts, election of board members, and authorization for capital increases), and the date of the meeting (May 14, 2025). This content perfectly matches the definition of materials shared during an Annual General Meeting.
2025-05-14 Norwegian

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.